Dividend re-investment time with a purchase of 30 shares of Pfizer at 40,16 USD per share. Pfizer has risks and pipeline execution is always challenging. Pfizer might also be subject of public opinion swings not to mention all the regulatory risks that come with the sector. However, as a whole the valuation seems favourable. Perhaps not cheap but at least not expensive and that’s good enough.